Neutralising antibodies against Ricin Toxin

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Prigent, Julie ^a   Panigai, Laetitia ^b   Lamourette, Patricia ^a   Sauvaire, Didier ^b   Devilliers, Karine ^a   Plaisance, Marc ^a   Volland, Hervé ^a   Créminon, Christophe ^a   Simon, Stéphanie ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b AFSSAPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RA36; MONOCLONAL ANTIBODY RB13; MONOCLONAL ANTIBODY RB14; MONOCLONAL ANTIBODY RB15; MONOCLONAL ANTIBODY RB24; MONOCLONAL ANTIBODY RB27; MONOCLONAL ANTIBODY RB34; MONOCLONAL ANTIBODY RB37; MONOCLONAL ANTIBODY RB42; MONOCLONAL ANTIBODY RB43; RICIN; RICIN A; RICIN B; UNCLASSIFIED DRUG; LACTOSE; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; FEMALE; IC 50; IMMUNOTHERAPY; IN VITRO STUDY; INTOXICATION; LD 50; MALE; MOUSE; NONHUMAN; PROTECTION; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING COMPETITION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; PROTEIN BINDING; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; JURKAT CELLS; LACTOSE; MALE; MICE; POISONING; PROTEIN BINDING; PROTEIN SUBUNITS; RICIN; SURFACE PLASMON RESONANCE;

EID: 79957476321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020166     Document Type: Article

References (37)

1. Audi J, Belson M, Patel M, Schier J, Osterloh J, (2005) Ricin poisoning: a comprehensive review. JAMA 294: 2342-2351.
2. Bigalke H, Rummel A, (2005) Medical aspects of toxin weapons. Toxicology 214: 210-220.
3. Binder P, Attre O, Boutin JP, Cavallo JD, Debord T, et al. (2003) Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp Immunol Microbiol Infect Dis 26: 401-421.
4. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S, (2005) The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 4: 281-297.
5. Cleveland DW, Fischer SG, Kirschner MW, Laemmli UK, (1977) Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem 252: 1102-1106.
6. Colombatti M, Johnson VG, Skopicki HA, Fendley B, Lewis MS, et al. (1987) Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. J Immunol 138: 3339-3344.
7. Dokmetjian J, Della VC, Lavigne V, de Lujan CM, Manghi MA, (2000) A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. Vaccine 18: 2698-2703.
8. Drake AW, Myszka DG, Klakamp SL, (2004) Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem 328: 35-43.
9. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM, (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
10. Endo Y, Mitsui K, Motizuki M, Tsurugi K, (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 262: 5908-5912.
11. Ey PL, Prowse SJ, Jenkin CR, (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15: 429-436.
12. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, et al. (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278: 399-411.
13. Grassi J, Frobert Y, Lamourette P, Lagoutte B, (1988) Screening of monoclonal antibodies using antigens labeled with acetylcholinesterase: application to the peripheral proteins of photosystem 1. Anal Biochem 168: 436-450.
14. Karlsson R, Michaelsson A, Mattsson L, (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145: 229-240.
15. Little SF, Leppla SH, Friedlander AM, (1990) Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun 58: 1606-1613.
16. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R Jr, et al. (2005) Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 73: 8362-8368.
17. Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, et al. (2004) Immunological characteristics associated with the protective efficacy of antibodies to ricin. J Immunol 172: 6221-6228.
18. Mantis NJ, McGuinness CR, Sonuyi O, Edwards G, Farrant SA, (2006) Immunoglobulin A antibodies against ricin A and B subunits protect epithelial cells from ricin intoxication. Infect Immun 74: 3455-3462.
19. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, et al. (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20: 597-601.
20. McGuinness CR, Mantis NJ, (2006) Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun 74: 3463-3470.
21. Neal LM, O'Hara J, Brey RN 3rd, Mantis NJ, (2010) A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 78: 552-61.
22. Nicolson GL, Blaustein J, Etzler ME, (1974) Characterization of two plant lectins from Ricinus communis and their quantitative interaction with a murine lymphoma. Biochemistry 13: 196-204.
23. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, et al. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 20; 99: 11346-11350.
24. O'Hara JM, Neal LM, McCarthy EA, Kasten-Jolly JA, Brey RN 3rd, et al. (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 43: 7035-46.
25. Olsnes S, Pihl A, (1973) Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis. Biochemistry 12: 3121-3126.
26. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, et al. (2004) Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 17: 391-397.
27. Reik LM, Maines SL, Ryan DE, Levin W, Bandiera S, et al. (1987) A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. J Immunol Methods 100: 123-130.
28. Roche JK, Stone MK, Gross LK, Lindner M, Seaner R, et al. (2008) Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 88: 1178-91.
29. Rutenber E, Robertus JD, (1991) Structure of ricin B-chain at 2.5 A resolution. Proteins 10: 260-269.
30. Sandvig K, van Deurs B, (1999) Endocytosis and intracellular transport of ricin: recent discoveries. FEBS Lett 452: 67-70.
31. Schep LJ, Temple WA, Butt GA, Beasley MD, (2009) Ricin as a weapon of mass terror--separating fact from fiction. Environ Int 35: 1267-1271.
32. Smallshaw JE, Richardson JA, Vitetta ES, (2007) RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25: 7459-7469.
33. Stechmann B, Bai SK, Gobbo E, Lopez R, Merer G, et al. (2010) Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 141: 231-242.
34. Tanaka KS, Chen XY, Ichikawa Y, Tyler PC, Furneaux RH, et al. (2001) Ricin A-chain inhibitors resembling the oxacarbenium ion transition state. Biochemistry 40: 6845-6851.
35. Tilahun ME, Rajagopalan G, Shah-Mahoney N, Lawlor RG, Tilahun AY, et al. (2010) Potent Neutralization of SEB by Synergistic Action of Chimeric Antibodies. Infect Immun 78: 2801-11.
36. Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, et al. (2006) A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A 103: 2268-2273.
37. Yan X, Hollis T, Svinth M, Day P, Monzingo AF, et al. (1997) Structure-based identification of a ricin inhibitor. J Mol Biol 266: 1043-1049.